Basal Cell Carcinoma Treatment Market Report, 2017-2025

Basal Cell Carcinoma Treatment Market (Treatment type - Surgical (Surgical Excision, Electrodessication & Cutterage, Moh's Surgery, and Cryosurgery), Drugs (Topical Treatment, Advanced Medication, and Other), and Others (Radiation Therapy, Photodynamic Therapy, and Laser Therapy); End-users- Hospitals, Specialty Clinics, and Others: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 - 2025

Basal Cell Carcinoma Treatment Market – Overview

Basal cell carcinomas are a type of malignant growth identified with the skin and are generally seen inside all diseases. Basal cell carcinoma ascends because of the uncommon and over the top development of basal cells. As basal cell carcinoma has a slower pace of development, they are treatable and they can cause insignificant harm in the event that they are gotten and early treatment is finished. Purposes behind basal cell carcinoma, different danger variables, and indications help in the early discovery, which helps in the treatment.

An increment in different kinds of skin problems, expanding recurrence of cuticular malignancies is the main considerations affecting the market. Besides, the developing geriatric populace, recurrence ascends in the repayment arrangements leaning toward the patients are supporting the development of the basal cell carcinoma treatment market. Expanding frequencies in skin growths because of different ecological elements like UV openness from the sun are the primary purposes behind skin sicknesses. Additionally, eventual outcomes of the treatment and endorsement time for the medications taking too long are the elements influencing the development of the market contrarily.

The global basal cell carcinoma treatment market is projected to rise at a CAGR of 9.20% during the forecast period of 2017 to 2025 and reach an estimated value of USD 10.14 bn from USD 4.66 bn earned in 2016 by the end of 2025.

basal cell carcinoma treatment market

Surgery Segment Owning Lion’s Share Owing to Availability of lesser treatment Choices

The global market for basal cell carcinoma treatment is categorized on the basis of treatment type, end user, and geography. In terms of treatment, the market is classified into surgical, drugs, and others. In terms of surgical treatment, the market is sub-categorized into surgical excision, electrodessication & Cutterage (ED&C), Moh’s Surgery, and Cryosurgery. Based on Drugs, the market is grouped into Advanced Medication, Topical Treatment, and others. Further categorization of others segment includes Laser therapy, specialty clinics, and hospitals.

In light of the treatment type, the surgery segment is expected to hold the larger share and will add to the fullest for the development of the basal cell carcinoma market all around the world. This is significantly credited to various surgeries related to the treatment of basal cell carcinoma combined with a few treatment choices. This has driven the surgeries portion to take a front lead for the development of the worldwide basal cell carcinoma treatment market.

Surgery strategy has been set up in basal cell carcinoma for the proficient and least conceivable repeat rates, most extreme fix rates, and top cosmetic outcomes among all the treatment approach for basal cell carcinoma. It is anticipated that surgery stays predominant throughout the following not many years affirming the strength of the by and large basal cell carcinoma treatment market. Extraction surgeries are by and large suggested for basal cell carcinomas that are probably going to repeat, for example, those that are framed on the chest, back, hands, and feet.

Increasing Prevalence of Skin Cancer will Promote Growth of Asia Pacific Market

North America holds the dominating piece of the pie for the global basal cell carcinoma market. This is exceptionally upheld because of the great predominance of basal cell carcinoma bringing about interest for quite some time choices. This is one of the unmistakable elements that add to the growth of the global basal cell carcinoma treatment market. Aside from that, Asia-Pacific is expected to develop at a higher speed in the impending a very long time by recording a noteworthy CAGR for the basal cell carcinoma market.

On the other side, the market in Asia Pacific is also expected to witness significant growth during the forecast period on account of major revenue generation from the Australian region. The Australian Government upholds giving school instruction with respect to skin malignant growth events. As Australia has the most elevated frequencies of skin tumors on the planet, Australia has been successfully controlling the prevalence of such malignant growth in the past and with more support, it is likely to improve with time. For people under 40, the frequency rate has dropped from a pinnacle of 13 cases for each 100,000 out of 2002 to an expected 9.4 per 100,000 in every 2016. This might bring new hope for the market growth in the coming years. The Government of Australia recognizes declining the predominance of basal cell carcinoma by offering lively bodies including Sports Medicine Australia's Ultraviolet (UV) Exposure and Heat Illness Guide. Furthermore, in 2016-17, US$ 2.3 Bn will be given to the nearby government in unfastened subsidizing under the Financial Assistance Grant Program that permits the gatherings the adaptability to apportion subsidizing to neighborhood needs.

The competitive landscape of the global basal cell carcinoma treatment market is consolidated in nature on account of the presence of a handful of players. Companies operating in this market are indulging in merger and acquisition activities to gain higher revenues in the forthcoming years. Besides this, extensive research and development technologies, and heavy investments on the same by all players are further expected to intensify the overall market competition in the long run. Some of the notable players of the global basal cell carcinoma treatment market include Mylan N.V., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., F. Hoffmann-La Roche Ltd., and Sun Pharmaceuticals Ltd.

The increasing popularity of farm tractors and collecting hardware is relied upon to help the general farm tire market development, as they are utilized for a long time machines, including nerve-racking, furrowing, plowing, and establishing machines. Developing mindfulness with respect to the significance of motorization in the agriculture area for the expansion of results is helping the development of the market. Demand for mechanically progressed tires, for example, with expanded flexion (IF) and strength farm tires, for example, consolidate tires, sprayer tires, and eco-accommodating tires are additionally expected to contribute toward the extension of the market.

The global basal cell carcinoma treatment market has been segmented as follows:

By Treatment Type

  • Surgical
    • Surgical Excision
    • Electrodessication & Cutterage (ED&C)
    • Moh's Surgery
    • Cryosurgery
  • Drugs
    • Topical Treatment
    • Advanced Medication
    • Other
  • Others
    • Radiation Therapy
    • Photodynamic Therapy (PDT)
    • Laser Therapy

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Australia & New Zealand
    • Japan
    • China
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • GCC
    • Rest of Middle East & Africa

Frequently Asked Questions

What is the total market worth of basal cell carcinoma treatment market?

The global basal cell carcinoma treatment market was worth US$4.66 bn and is projected to reach a value of US$10.14 bn by the end of 2025

What is the anticipated CAGR of the basal cell carcinoma treatment market in the forecast period?

Basal cell carcinoma treatment market is anticipated to grow at a CAGR of 9.2% during the forecast period

Which region is expected to project the highest market share in the global basal cell carcinoma treatment market?

North America accounted for a major share of the global basal cell carcinoma treatment market

What are the key driving factors for the growth of the basal cell carcinoma treatment market?

Basal cell carcinoma treatment market is driven by increase in geriatric population and rising demand for better disease treatments in emerging economies

Who are the key players in the global basal cell carcinoma treatment market?

Key players in the global basal cell carcinoma treatment market include Mylan N.V., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., F. Hoffmann-La Roche Ltd., and Sun Pharmaceuticals Ltd.

    Section 1 Preface 
    1.1 Report Scope and Market Segmentation 
    1.2 Research Highlights

    Section 2 Assumptions and Research Methodology 
    2.1 Assumptions
    2.2 Research Methodology

    Section 3 Executive Summary
    3.1 Global Basal Cell Carcinoma Treatment: Market Snapshot
    3.2 Market Share Analysis by Region, 2016
    3.3 Market Opportunity Map

    Section 4 Market Overview
    4.1 Market Overview
    4.2 Global Basal Cell Carcinoma Treatment Market: Market Indicators
    4.3 Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2015–2025
    4.4 Global Basal Cell Carcinoma Treatment Market: Market Outlook

    Section 5 Market Dynamics
    5.1 Drivers and Restraints Snapshot Analysis
    5.2 Drivers
          5.2.1 Changing Environmental Factors
          5.2.2 Stringent Regulatory Policies Assuring Better Product Quality
          5.2.3 Favorable Reimbursement Scenario
          5.2.4 Growing Disease Awareness Initiatives
          5.2.5 Rise in Geriatric Population
    5.3 Restraints
          5.3.1 Lack of Awareness in Developing Countries
          5.3.2 High Cost of Treatment 
    5.4 Opportunities
          5.4.1 Emerging Markets in Developing Countries
          5.4.2 Alternative Potential Therapies
    5.5 Key Trends
    5.6 Basal Cell Carcinoma Treatment Market: Value Chain Analysis 
    5.7 Pipeline Analysis: Basal Cell Carcinoma Market
    5.8 Key Success Factors of Top 3 Companies
    5.9 Healthcare Overview 

    Section 6 Basal Cell Carcinoma Treatment Market Analysis, by Treatment
    6.1 Introduction
    6.2 Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment
    6.3 Basal Cell Carcinoma Treatment Market Forecast, by Treatment
          6.3.1 Surgical
                  6.3.1.1 Surgical Excision
                  6.3.1.2 Electrodessication & Cutterage (ED&C)
                  6.3.1.3 Moh's Surgery
                  6.3.1.4 Cryosurgery
          6.3.2 Drugs
                  6.3.2.1 Topical Treatment
                  6.3.2.2 Advanced Medication
                  6.3.2.3 Other
          6.3.3 Others
                  6.3.3.1 Radiation Therapy
                  6.3.3.2 Photodynamic Therapy (PDT)
                  6.3.3.3 Laser Therapy
    6.4 Market Attractiveness Analysis, by Treatment

    Section 7 Basal Cell Carcinoma Treatment Market Analysis, by End User
    7.1 Introduction
    7.2 Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user
    7.3 Basal Cell Carcinoma Treatment Market Forecast, by End-user
          7.3.1 Hospitals
          7.3.2 Specialty Clinics
          7.3.3 Others
    7.4Market Attractiveness Analysis, by End-user

    Section 8 Basal Cell Carcinoma Treatment Market Analysis, by Region
    8.1 Global Basal Cell Carcinoma Treatment Market, Global Market Scenario
    8.2 Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by Region
    8.3 Basal Cell Carcinoma Treatment Market Forecast, by Region
    8.4 Market Attractiveness Analysis, by Region

    Section 9 North America Basal Cell Carcinoma Treatment Market Analysis
    9.1 Regional Outlook
    9.2 Market Overview
    9.3 Market Analysis, by Treatment
          9.3.1 Market Value Share Analysis, by Treatment
          9.3.2 Market Size (US$ Mn) Forecast, by Treatment
                  9.3.2.1 Surgical
                            9.3.2.1.1 Surgical Excision
                            9.3.2.1.2 Electrodessication & Cutterage (ED&C)
                            9.3.2.1.3 Moh's Surgery
                            9.3.2.1.4 Cryosurgery
                  9.3.2.2 Drugs
                            9.3.2.2.1 Topical Treatment
                            9.3.2.2.2 Advanced Medication
                            9.3.2.2.3 Other
                  9.3.2.3 Others
                            9.3.2.3.1 Radiation Therapy
                            9.3.2.3.2 Photodynamic Therapy (PDT)
                            9.3.2.3.3 Laser Therapy
    9.4 Market Analysis, by End-user
          9.4.1 Market Value Share Analysis, by End-user
          9.4.2 Market Size (US$ Mn) Forecast, by End-user
                  9.4.2.1 Hospitals
                  9.4.2.2 Specialty Clinics
                  9.4.2.3 Others
    9.5 Market Analysis, by Country
          9.5.1 Market Value Share Analysis, by Country
          9.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
                  9.5.2.1 U.S.
                  9.5.2.2 Canada
    9.6 Market Attractiveness Analysis
          9.6.1 by Country
          9.6.2 by Treatment
          9.6.3 by End-user

    Section 10 Europe Basal Cell Carcinoma Treatment Market Analysis
    10.1 Regional Outlook
    10.2 Market Overview
    10.3 Market Analysis, by Treatment
          10.3.1 Market Value Share Analysis, by Treatment
          10.3.2 Market Size (US$ Mn) Forecast, by Treatment
                  10.3.2.1 Surgical
                            10.3.2.1.1 Surgical Excision
                            10.3.2.1.2 Electrodessication & Cutterage (ED&C)
                            10.3.2.1.3 Moh's Surgery
                            10.3.2.1.4 Cryosurgery
                  10.3.2.2 Drugs
                            10.3.2.2.1 Topical Treatment
                            10.3.2.2.2 Advanced Medication
                            10.3.2.2.3 Other
                  10.3.2.3 Others
                            10.3.2.3.1 Radiation Therapy
                            10.3.2.3.2 Photodynamic Therapy (PDT)
                            10.3.2.3.3 Laser Therapy
    10.4 Market Analysis, by End-user
          10.4.1 Market Value Share Analysis, by End-user
          10.4.2 Market Size (US$ Mn) Forecast, by End-user
                  10.4.2.1 Hospitals
                  10.4.2.2 Specialty Clinics
                  10.4.2.3 Others
    10.5 Market Analysis, by Country
          10.5.1 Market Value Share Analysis, by Country
          10.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
                  10.5.2.1 UK
                  10.5.2.2 Germany
                  10.5.2.3 France
                  10.5.2.4 Spain
                  10.5.2.5 Italy
                  10.5.2.6 Rest of Europe
    10.6 Market Attractiveness Analysis
          10.6.1 by Country
          10.6.2 by Treatment
          10.6.3 by End-user

    Section 11 Asia Pacific Basal Cell Carcinoma Treatment Market Analysis
    11.1 Regional Outlook
    11.2 Market Overview
    11.3 Market Analysis, by Treatment
          11.3.1 Market Value Share Analysis, by Treatment
          11.3.2 Market Size (US$ Mn) Forecast, by Treatment
                  11.3.2.1 Surgical
                            11.3.2.1.1 Surgical Excision
                            11.3.2.1.2 Electrodessication & Cutterage (ED&C)
                            11.3.2.1.3 Moh's Surgery
                            11.3.2.1.4 Cryosurgery
                  11.3.2.2 Drugs
                            11.3.2.2.1 Topical Treatment
                            11.3.2.2.2 Advanced Medication
                            11.3.2.2.3 Other
                  11.3.2.3 Others
                            11.3.2.3.1 Radiation Therapy
                            11.3.2.3.2 Photodynamic Therapy (PDT)
                            11.3.2.3.3 Laser Therapy
    11.4 Market Analysis, by End-user
          11.4.1 Market Value Share Analysis, by End-user
          11.4.2 Market Size (US$ Mn) Forecast, by End-user
                  11.4.2.1 Hospitals
                  11.4.2.2 Specialty Clinics
                  11.4.2.3 Others
    11.5 Market Analysis, by Country
          11.5.1 Market Value Share Analysis, by Country
          11.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
                  11.5.2.1 Australia & New Zealand
                  11.5.2.2 Japan
                  11.5.2.3 China
                  11.5.2.4 Rest of APAC
    11.6 Market Attractiveness Analysis
          11.6.1 by Country
          11.6.2 by Treatment
          11.6.3 by End-user

    Section 12 Latin America Basal Cell Carcinoma Treatment Market Analysis
    12.1 Regional Outlook
    12.2 Market Overview
    12.3 Market Analysis, by Treatment
          12.3.1 Market Value Share Analysis, by Treatment
          12.3.2 Market Size (US$ Mn) Forecast, by Treatment
                  12.3.2.1 Surgical
                            12.3.2.1.1 Surgical Excision
                            12.3.2.1.2 Electrodessication & Cutterage (ED&C)
                            12.3.2.1.3 Moh's Surgery
                            12.3.2.1.4 Cryosurgery
                  12.3.2.2 Drugs
                            12.3.2.2.1 Topical Treatment
                            12.3.2.2.2 Advanced Medication
                            12.3.2.2.3 Other
                  12.3.2.3 Others
                            12.3.2.3.1 Radiation Therapy
                            12.3.2.3.2 Photodynamic Therapy (PDT)
                            12.3.2.3.3 Laser Therapy
    12.4 Market Analysis, by End-user
          12.4.1 Market Value Share Analysis, by End-user
          12.4.2 Market Size (US$ Mn) Forecast, by End-user
                  12.4.2.1 Hospitals
                  12.4.2.2 Specialty Clinics
                  12.4.2.3 Others
    12.5 Market Analysis, by Country
          12.5.1 Market Value Share Analysis, by Country
          12.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
                  12.5.2.1 Brazil
                  12.5.2.2 Mexico
                  12.5.2.3 Rest of LATAM
    12.6 Market Attractiveness Analysis
          12.6.1 by Country
          12.6.2 by Treatment
          12.6.3 by End-user

    Section 13 Middle East & Africa Basal Cell Carcinoma Treatment Market Analysis
    13.1 Regional Outlook
    13.2 Market Overview
    13.3 Market Analysis, by Treatment
          13.3.1 Market Value Share Analysis, by Treatment
          13.3.2 Market Size (US$ Mn) Forecast, by Treatment
                  13.3.2.1 Surgical
                            13.3.2.1.1 Surgical Excision
                            13.3.2.1.2 Electrodessication & Cutterage (ED&C)
                            13.3.2.1.3 Moh's Surgery
                            13.3.2.1.4 Cryosurgery
                  13.3.2.2 Drugs
                            13.3.2.2.1 Topical Treatment
                            13.3.2.2.2 Advanced Medication
                            13.3.2.2.3 Other
                  13.3.2.3 Others
                            13.3.2.3.1 Radiation Therapy
                            13.3.2.3.2 Photodynamic Therapy (PDT)
                            13.3.2.3.3 Laser Therapy
    13.4 Market Analysis, by End-user
          13.4.1 Market Value Share Analysis, by End-user
          13.4.2 Market Size (US$ Mn) Forecast, by End-user
                  13.4.2.1 Hospitals
                  13.4.2.2 Specialty Clinics
                  13.4.2.3 Others
    13.5 Market Analysis, by Country
          13.5.1 Market Value Share Analysis, by Country
          13.5.2 Market Size (US$ Mn) Forecast, by Country, 2017–2025
                  13.5.2.1 South Africa
                  13.5.2.2 GCC Countries
                  13.5.2.3 Rest of MEA
    13.6 Market Attractiveness Analysis
          13.6.1 by Country
          13.6.2 by Treatment
          13.6.3 by End-user

    Section 14 Company Profiles
    14.1 Basal Cell Carcinoma Treatment Market Share Analysis, by Company (2016)
    14.2 Company Profiles
          14.2.1 Sun Pharmaceuticals Ltd.
                  14.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
                  14.2.1.2 Financial Overview
                  14.2.1.3 Product Portfolio
                  14.2.1.4 SWOT Analysis
                  14.2.1.5 Strategic Overview
          14.2.2 Valeant Pharmaceuticals International, Inc.
                  14.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
                  14.2.2.2 Financial Overview
                  14.2.2.3 Product Portfolio
                  14.2.2.4 SWOT Analysis
                  14.2.2.5 Strategic Overview
          14.2.3 Mylan N.V.
                  14.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
                  14.2.3.2 Financial Overview
                  14.2.3.3 Product Portfolio
                  14.2.3.4 SWOT Analysis
                  14.2.3.5 Strategic Overview
          14.2.4 F. Hoffmann-La Roche Ltd. 
                  14.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
                  14.2.4.2 Financial Overview
                  14.2.4.3 Product Portfolio
                  14.2.4.4 SWOT Analysis
                  14.2.4.5 Strategic Overview
          14.2.5 Merck & Co., Inc.
                  14.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
                  14.2.5.2 Financial Overview
                  14.2.5.3 Product Portfolio
                  14.2.5.4 SWOT Analysis
                  14.2.5.5 Strategic Overview

    List of Tables

    Table 01: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
    Table 02: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment, 2017–2025
    Table 03: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment, 2017–2025
    Table 04: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2017–2025
    Table 05: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
    Table 06: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2025
    Table 07: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
    Table 08: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment
    Table 09: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment
    Table 10: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment
    Table 11: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
    Table 12: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
    Table 13: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
    Table 14: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment, 2017–2025
    Table 15: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment, 2017–2025
    Table 16: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2017–2025
    Table 17: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
    Table 18: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
    Table 19: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
    Table 20: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment
    Table 21: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment, 2017–2025
    Table 22: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2017–2025
    Table 23: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
    Table 24: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2025
    Table 25: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2025
    Table 26: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment
    Table 27: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment
    Table 28: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment
    Table 29: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user, 2017–2025
    Table 30: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 31: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Treatment
    Table 32: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Surgical Treatment, 2017–2025
    Table 33: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Drugs Treatment, 2017–2025
    Table 34: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Other Treatment, 2017–2025
    Table 35: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by End-user
    Table 36: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, by Country, 2015–2025

    List of Figures

    Figure 01: Basal Cell Carcinoma Treatment Market Snapshot
    Figure 02: Global Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2015–2025
    Figure 03: Market Value Share by Treatment (2016)
    Figure 04: Market Value Share by End-user (2016)
    Figure 05: Market Value Share by Region (2016)
    Figure 06: Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 07: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Surgical Treatment, 2015–2025
    Figure 08: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Drugs Treatment, 2015–2025
    Figure 09: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
    Figure 10: Global Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment
    Figure 11: Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
    Figure 12: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2015–2025
    Figure 13: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Specialty Clinics, 2015–2025
    Figure 14: Global Basal Cell Carcinoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
    Figure 15: Global Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
    Figure 16: Global Basal Cell Carcinoma Treatment Market Value Share Analysis, by Region, 2016 and 2025
    Figure 17: Global Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Region
    Figure 18: North America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2017–2025
    Figure 19: North America Market Attractiveness Analysis, by Country
    Figure 20: North America Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 21: North America Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
    Figure 22: North America Basal Cell Carcinoma Treatment Market Value Share Analysis, by Country, 2016 and 2025
    Figure 23: North America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment 
    Figure 24: North America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
    Figure 25: Europe Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2017–2025
    Figure 26: Europe Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Country
    Figure 27: Europe Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 28: Europe Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
    Figure 29: Europe Basal Cell Carcinoma Treatment Market Value Share Analysis, by Country, 2016 and 2025
    Figure 30: Europe Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment
    Figure 31: Europe Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
    Figure 32: Asia Pacific Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2015–2025
    Figure 33: Asia Pacific Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Country
    Figure 34: Asia Pacific Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 35: Asia Pacific Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
    Figure 36: Asia Pacific Basal Cell Carcinoma Treatment Market Value Share Analysis, by Country, 2016 and 2025
    Figure 37: Asia Pacific Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment
    Figure 38: Asia Pacific Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
    Figure 39: Latin America Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2015–2025
    Figure 40: Latin America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Country
    Figure 41: Latin America Basal Cell Carcinoma Treatment Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 42: Latin America Basal Cell Carcinoma Treatment Market Value Share Analysis, by End-user, 2016 and 2025
    Figure 43: Latin America Basal Cell Carcinoma Treatment Market Value Share Analysis, by Country, 2016 and 2025
    Figure 44: Latin America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by Treatment
    Figure 45: Latin America Basal Cell Carcinoma Treatment Market Attractiveness Analysis, by End-user
    Figure 46: Middle East & Africa Basal Cell Carcinoma Treatment Market Size (US$ Mn) Forecast, 2015–2025
    Figure 47: Middle East & Africa Market Attractiveness Analysis, by Country
    Figure 48: Middle East & Africa Market Value Share Analysis, by Treatment, 2016 and 2025
    Figure 49: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2025
    Figure 50: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2025
    Figure 51: Middle East & Africa Market Attractiveness Analysis, by Treatment
    Figure 52: Middle East & Africa Market Attractiveness Analysis, by End-user
    Figure 53: Global Basal Cell Carcinoma Market Share Analysis, by Company (2016)
    Figure 54: Sun Pharmaceuticals Ltd Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 55: Sun Pharmaceuticals Ltd Breakdown of Net Sales, By Business Segments, 2017
    Figure 56: Sun Pharmaceuticals Ltd Breakdown of Net Sales, by Region, 2017
    Figure 57: Sun Pharmaceuticals Ltd R&D Expense (US$ Bn) & Y-o-Y Growth (%), 2015–2017
    Figure 58: Valeant Pharmaceuticals International, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 59: Valeant Pharmaceuticals International, Inc. Marketing and R&D Expenses, 2015–2016
    Figure 60: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, by Region, 2016
    Figure 61: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, by Business Segment, 2016
    Figure 62: Mylan N.V. Marketing and R&D Expenses, 2015–2016
    Figure 63: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
    Figure 64: Mylan N.V. Breakdown of Net Sales, by Region, 2016
    Figure 65: F. Hoffmann-La Roche Ltd.  Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
    Figure 66: F. Hoffmann-La Roche Ltd. R&D Expenses, 2014–2016
    Figure 67: F. Hoffmann-La Roche Ltd.  Breakdown of Net Sales, by Region, 2016
    Figure 68: Merck & Co., Inc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
    Figure 69: Merck & Co., Inc. Breakdown of Net Sales, by Region, 2016
    Figure 70: Merck & Co., Inc. Breakdown of Net Sales, by Business Segment, 2016
    Figure 71: Merck & Co., Inc. R&D Expense (US$ Bn) & Y-o-Y Growth (%), 2014–2016

Copyright © Transparency Market Research, Inc. All Rights reserved